Tafamidis was approved by the US Food and Drug Administration for the treatment of wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy in 2019, whereas patisiran was approved for the treatment of hereditary transthyretin amyloid polyneuropathy, but not amyloid cardiomyopathy, in 2018. The gene discussed is TTR; the disease is cardiac amyloidosis.